Executive readout · one minute
Call research workspace
Read the call alongside every captured source. Audio, transcript, slides and SEC filings stay in one workspace.
Earnings call · FY2026 Q2
Executive readout · one minute
Read the call alongside every captured source. Audio, transcript, slides and SEC filings stay in one workspace.
Forward guidance
15 guided metrics
Management's latest ranges and targets are included below.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
From the 8-K filed Jul 28, 2026.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
Total Revenues
table
2026 Expectations
|
$1.73B – $1.84B | — | |
|
VIVITROL Net Sales
table
2026 Expectations
|
$460M – $480M | — | |
|
ARISTADA Net Sales
table
2026 Expectations
|
$365M – $385M | — | |
|
LYBALVI Net Sales
table
2026 Expectations
|
$380M – $400M | — | |
|
Cost of Goods Sold
table
2026 Expectations
|
$320M – $340M | GAAP | |
|
LUMRYZ Net Sales
table
Feb. 12, 2026 – Dec. 31, 2026
|
$315M – $335M | — | |
|
R&D Expenses
table
2026 Expectations
|
$445M – $485M | GAAP | |
|
SG&A Expenses
table
2026 Expectations
|
$890M – $930M | GAAP | |
|
Amortization of Intangible Assets
table
2026 Expectations
|
$75M – $85M | GAAP | |
|
Change in the Fair Value of Contingent Consideration
table
2026 Expectations
|
$25M | GAAP | |
|
Net Tax Benefit
table
2026 Expectations
|
$0 | — | |
|
Net Interest Expense
table
2026 Expectations
|
$75M – $85M | — | |
|
GAAP Net Loss
table
2026 Expectations
|
$-115M – $-95M | GAAP | |
|
EBITDA
table
2026 Expectations
|
$75M – $95M | Non-GAAP | |
|
Adjusted EBITDA
table
2026 Expectations
|
$370M – $410M | Non-GAAP |
How the reported period landed and where the business moved.
SEC filing · Item 2.02
Filed Jul 28, 2026 · complete as-filed document
SEC periodic report
Filed Jul 28, 2026 · complete as-filed document